Dale J B, Cleary P P, Fischetti V A, Kasper D L, Musser J M, Zabriskie J B
University of Tennessee, Memphis, USA.
Adv Exp Med Biol. 1997;418:863-8. doi: 10.1007/978-1-4899-1825-3_205.
The data presented above provide a broad overview of ongoing work to develop vaccines against group A and group B streptococcal infections. The encouraging results of human trials with conjugate group B polysaccharide vaccines suggest that this approach will lead to a safe and effective method for preventing these devastating infections in newborn infants. The results of preclinical studies of the various strategies to develop group A streptococcal vaccines are also encouraging. Whether one approach will be more advantageous or efficacious than another will need to await clinical trials. Nevertheless, we predict that in the next decade we will make significant strides in preventing streptococcal infections and their complications.
上述数据全面概述了目前针对A组和B组链球菌感染开发疫苗的工作进展。B组多糖结合疫苗人体试验取得的令人鼓舞的结果表明，这种方法将带来一种安全有效的方式，用于预防新生儿感染这些极具破坏性的病菌。开发A组链球菌疫苗的各种策略的临床前研究结果同样令人鼓舞。一种方法是否会比另一种方法更具优势或更有效，还需等待临床试验的验证。尽管如此，我们预计在未来十年里，我们将在预防链球菌感染及其并发症方面取得重大进展。
